Switch to:
Also traded in: Canada

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.38
TBUFF's Cash to Debt is ranked lower than
71% of the 723 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.47 vs. TBUFF: 0.38 )
Ranked among companies with meaningful Cash to Debt only.
TBUFF' s Cash to Debt Range Over the Past 10 Years
Min: 0.23  Med: 10000.00 Max: No Debt
Current: 0.38
Equity to Asset 0.43
TBUFF's Equity to Asset is ranked lower than
76% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. TBUFF: 0.43 )
Ranked among companies with meaningful Equity to Asset only.
TBUFF' s Equity to Asset Range Over the Past 10 Years
Min: 0.02  Med: 0.86 Max: 0.97
Current: 0.43
0.02
0.97
F-Score: 3
Z-Score: 0.81
M-Score: -0.78
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -4.13
TBUFF's Operating margin (%) is ranked lower than
78% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.51 vs. TBUFF: -4.13 )
Ranked among companies with meaningful Operating margin (%) only.
TBUFF' s Operating margin (%) Range Over the Past 10 Years
Min: -94.74  Med: -15.52 Max: 27.69
Current: -4.13
-94.74
27.69
Net-margin (%) -51.44
TBUFF's Net-margin (%) is ranked lower than
87% of the 684 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.44 vs. TBUFF: -51.44 )
Ranked among companies with meaningful Net-margin (%) only.
TBUFF' s Net-margin (%) Range Over the Past 10 Years
Min: -89.59  Med: -10.02 Max: 28.68
Current: -51.44
-89.59
28.68
ROE (%) -35.83
TBUFF's ROE (%) is ranked lower than
85% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.23 vs. TBUFF: -35.83 )
Ranked among companies with meaningful ROE (%) only.
TBUFF' s ROE (%) Range Over the Past 10 Years
Min: -64.08  Med: -4.40 Max: 32.96
Current: -35.83
-64.08
32.96
ROA (%) -17.41
TBUFF's ROA (%) is ranked lower than
82% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. TBUFF: -17.41 )
Ranked among companies with meaningful ROA (%) only.
TBUFF' s ROA (%) Range Over the Past 10 Years
Min: -41.89  Med: -3.56 Max: 29.1
Current: -17.41
-41.89
29.1
ROC (Joel Greenblatt) (%) -980.72
TBUFF's ROC (Joel Greenblatt) (%) is ranked lower than
91% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.81 vs. TBUFF: -980.72 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TBUFF' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -544.61  Med: -65.49 Max: 122.99
Current: -980.72
-544.61
122.99
Revenue Growth (3Y)(%) 10.10
TBUFF's Revenue Growth (3Y)(%) is ranked higher than
61% of the 581 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. TBUFF: 10.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TBUFF' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -4.4  Med: 18.60 Max: 38.7
Current: 10.1
-4.4
38.7
EBITDA Growth (3Y)(%) -15.70
TBUFF's EBITDA Growth (3Y)(%) is ranked lower than
78% of the 528 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. TBUFF: -15.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TBUFF' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -41.50 Max: 18.6
Current: -15.7
0
18.6
EPS Growth (3Y)(%) 51.30
TBUFF's EPS Growth (3Y)(%) is ranked higher than
92% of the 483 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. TBUFF: 51.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TBUFF' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -76.8  Med: 18.80 Max: 188.9
Current: 51.3
-76.8
188.9
» TBUFF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with TBUFF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 11.67
TBUFF's Forward P/E is ranked higher than
77% of the 413 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.38 vs. TBUFF: 11.67 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 3.22
TBUFF's P/B is ranked lower than
63% of the 927 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.50 vs. TBUFF: 3.22 )
Ranked among companies with meaningful P/B only.
TBUFF' s P/B Range Over the Past 10 Years
Min: 1.07  Med: 2.80 Max: 77
Current: 3.22
1.07
77
P/S 5.10
TBUFF's P/S is ranked lower than
84% of the 927 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.64 vs. TBUFF: 5.10 )
Ranked among companies with meaningful P/S only.
TBUFF' s P/S Range Over the Past 10 Years
Min: 1  Med: 3.76 Max: 58.75
Current: 5.1
1
58.75
Current Ratio 0.60
TBUFF's Current Ratio is ranked lower than
96% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. TBUFF: 0.60 )
Ranked among companies with meaningful Current Ratio only.
TBUFF' s Current Ratio Range Over the Past 10 Years
Min: 0.46  Med: 5.45 Max: 21
Current: 0.6
0.46
21
Quick Ratio 0.52
TBUFF's Quick Ratio is ranked lower than
93% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. TBUFF: 0.52 )
Ranked among companies with meaningful Quick Ratio only.
TBUFF' s Quick Ratio Range Over the Past 10 Years
Min: 0.38  Med: 4.87 Max: 18.34
Current: 0.52
0.38
18.34
Days Inventory 69.99
TBUFF's Days Inventory is ranked higher than
77% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 119.42 vs. TBUFF: 69.99 )
Ranked among companies with meaningful Days Inventory only.
TBUFF' s Days Inventory Range Over the Past 10 Years
Min: 46.89  Med: 190.04 Max: 246.69
Current: 69.99
46.89
246.69
Days Sales Outstanding 91.37
TBUFF's Days Sales Outstanding is ranked lower than
61% of the 584 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.67 vs. TBUFF: 91.37 )
Ranked among companies with meaningful Days Sales Outstanding only.
TBUFF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 16.08  Med: 36.81 Max: 78.31
Current: 91.37
16.08
78.31

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.24
TBUFF's Price/Median PS Value is ranked lower than
55% of the 913 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. TBUFF: 1.24 )
Ranked among companies with meaningful Price/Median PS Value only.
TBUFF' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.29  Med: 1.18 Max: 22.09
Current: 1.24
0.29
22.09
Price/Graham Number 1.29
TBUFF's Price/Graham Number is ranked higher than
77% of the 660 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.21 vs. TBUFF: 1.29 )
Ranked among companies with meaningful Price/Graham Number only.
TBUFF' s Price/Graham Number Range Over the Past 10 Years
Min: 0.65  Med: 1.75 Max: 103
Current: 1.29
0.65
103
Earnings Yield (Greenblatt) (%) -6.72
TBUFF's Earnings Yield (Greenblatt) (%) is ranked lower than
83% of the 720 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. TBUFF: -6.72 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TBUFF' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -6.72  Med: 6.20 Max: 28.6
Current: -6.72
-6.72
28.6

More Statistics

Revenue(Mil) $21
EPS $ -0.10
Beta0.99
Short Percentage of Float0.71%
52-Week Range $0.50 - 1.86
Shares Outstanding(Mil)126.24

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 23 29 37 39
EPS($) -0.07 0.02 0.08 0.04
EPS without NRI($) -0.07 0.02 0.08 0.04

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:TRX.Canada,
Tribute Pharmaceuticals Canada Inc was incorporated under the Business Corporations Act (Ontario) on November 14, 1994. The Company is a specialty pharmaceutical company. It conducts acquisition, licensing, development and promotion of healthcare products in Canada. It sells Uracyst and NeoVisc internationally through a number of strategic partnerships. The Company's portfolio of assets includes nine product lines, eight of which are on the market in Canada, including: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, Collatamp G, and MycoVa. The Company markets its products in Canada through its own sales force and currently has licensing agreements for the distribution of select products in over 20 countries, and continues to expand this footprint. It faces product competition from companies marketing competing pharmaceutical products and medical devices in Canada. The Company's operations are or may be subject to various federal, provincial, state and local laws, regulations and recommendations relating to the marketing of products and relationships with treating physicians, data protection, safe working conditions, laboratory and manufacturing practices, the export of products to certain countries and the purchase, storage, movement, use and disposal of hazardous or potentially hazardous substances.
» More Articles for TBUFF

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
TRIBUTE PHARMACEUTICALS CANADA INC. Files SEC form 8-K, Regulation FD Disclosure, Financial... Feb 05 2016
POZEN And Tribute Combine To Create Aralez Pharmaceuticals Inc. Feb 05 2016
POZEN And Tribute Combine To Create Aralez Pharmaceuticals Inc. Feb 05 2016
TRIBUTE PHARMACEUTICALS CANADA INC. Financials Feb 04 2016
POZEN Inc. Announces Stockholder Approval of its Transaction with Tribute Pharmaceuticals Canada... Feb 02 2016
POZEN Inc. Announces Stockholder Approval of its Transaction with Tribute Pharmaceuticals Canada... Feb 02 2016
TRIBUTE PHARMACEUTICALS CANADA INC. Files SEC form 8-K, Submission of Matters to a Vote of Security... Feb 01 2016
Tribute Announces Results of Shareholder Vote Feb 01 2016
Tribute Announces Results of Shareholder Vote Feb 01 2016
TRIBUTE PHARMACEUTICALS CANADA INC. Files SEC form 8-K, Regulation FD Disclosure, Financial... Jan 21 2016
Leading Independent Advisors Recommend That Tribute Shareholders Vote FOR the Transaction Jan 21 2016
Leading Independent Advisors Recommend That Tribute Shareholders Vote FOR the Transaction Jan 21 2016
TRIBUTE PHARMACEUTICALS CANADA INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events,... Jan 11 2016
Tribute Mails Materials in Connection With Special Meeting of Shareholders to Approve Transaction... Jan 11 2016
Tribute Mails Materials in Connection With Special Meeting of Shareholders to Approve Transaction... Jan 11 2016
TRIBUTE PHARMACEUTICALS CANADA INC. Files SEC form 8-K, Regulation FD Disclosure, Financial... Jan 04 2016
Tribute Pharmaceuticals Receives Notice of Allowance for Canadian Patent Expanding Cambia(R) Use in... Jan 04 2016
Tribute Pharmaceuticals Receives Notice of Allowance for Canadian Patent Expanding Cambia(R) Use in... Jan 04 2016
POZN: Shareholder Meetings Set for Early February; YOSPRALA® NDA to be re-filed in 2Q16 Dec 29 2015
RETRANSMISSION: Tribute Schedules Special Shareholder Meeting for February 1, 2016 Dec 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK